{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:58:59Z","timestamp":1793271539650,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006256","name":"Universit\u00e0 degli Studi dell'Aquila","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The idea of psoriatic disease continuum has been progressively prompted based on the advances of the knowledge about the pathogenic steps underpinning the occurrence of psoriasis (PSO) and psoriatic arthritis (PSA). To evaluate biomolecules (inflammatory cytokines, inflammatory chemokines, cell adhesion and cellular mediators) in na\u00efve patients with PSO, PSA with PSO, and PSA sine PSO. To stratify the results considering the presence of psoriatic nail involvement, extensive skin disease and obesity evaluating all involved patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>By multiplex technology, 20 serum biomolecules were assessed with the inclusion of pro-inflammatory cytokines (GM-CSF, IFN-\u03b3, IL-1\u03b1, IL-1\u03b2, IL-6, IL-8, IL-12p70, IL-17A, IL-23, TNF), anti-inflammatory cytokines (IFN-\u03b1, IL-4, IL-10, IL-13), inflammatory chemokines (IP-10, MCP-1, MIP-1\u03b1, MIP-1\u03b2), cell adhesion and cellular mediators (ICAM-1, E-selectin, P-selectin). The assessment of possible statistical differences between the means of the three groups was performed by One-Way ANOVA. In addition, by non-parametric T-tests, we stratified the results according to selected clinical characteristics (psoriatic nail involvement, PASI \u2265 10, BMI \u2265 30).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 80 assessed na\u00efve patients, patients with PSO showed significant increases of E-selectin (p=0.021) and IL-8 (0.041) than other groups. In patients with PSA with PSO, significant higher levels of ICAM-1 were observed (p=0.009) than other groups. We did not observe further differences comparing pro-inflammatory and anti-inflammatory cytokines, inflammatory chemokines, and cell adhesion and cellular mediators in patients with PSO, PSA with PSO, and PSA sine PSO. Patients with psoriatic onychopathy showed significant increased levels of ICAM-1 (p=0.010) and IP-10 (0.030) than others. In patients with PASI \u2265 10, significantly enhanced values of IL-8 (p=0.004), TNF (p=0.013), E-selectin (p=0.004), MIP-1\u03b1 (p=0.003), and MIP-1\u03b2 (p=0.039). In patients with BMI \u2265 30, significantly higher levels of E-selectin were pointed out (p=0.035) than others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings may suggest that a similar cytokine profile may characterize na\u00efve patients with PSO, PSA with PSO, and PSA sine PSO, reinforcing the concept of psoriatic disease continuum. However, some differences may be also shown, underlying possible pathogenic differences and leading to the clinical heterogeneity of these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1229516","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T14:50:09Z","timestamp":1689259809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Cytokine profile characterization of na\u00efve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum"],"prefix":"10.3389","volume":"14","author":[{"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Berardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Gianneramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00578-2","article-title":"Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study","volume":"17","author":"Perez-Chada","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19886505","article-title":"The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis","volume":"11","author":"Frischknecht","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108318","article-title":"Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: a review of literature","volume":"211","author":"Pouw","year":"2020","journal-title":"Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.14","article-title":"Mechanistic biomarkers for clinical decision making in rheumatic diseases","volume":"9","author":"Robinson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076384","article-title":"Targeted therapies in psoriatic arthritis\u2013an update","volume":"24","author":"Sundanum","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.berh.2022.101809","article-title":"Horizon scan: state-of-the-art therapeutics for psoriatic arthritis","volume":"36","author":"Hutton","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-022-01568-4","article-title":"Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study","volume":"127","author":"Ruscitti","year":"2022","journal-title":"Radiol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190054","article-title":"Psoriatic arthritis, psoriatic disease, or psoriatic syndrome","volume":"46","author":"Lubrano","year":"2019","journal-title":"J Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114294","article-title":"Targeting Nrf2 with 3 H-1,2-dithiole-3-thione to moderate OXPHOS-driven oxidative stress attenuates IL-17A-induced psoriasis","volume":"159","author":"Liu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1999.00401.x","article-title":"Soluble E-selectin serum levels correlate with disease activity in psoriatic patients","volume":"24","author":"Szepietowski","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"B19","first-page":"17","article-title":"Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis\u2013correlation with disease activity","volume":"134","author":"Czech","year":"1996","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103207","article-title":"Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3\/4 and FOXP3) activation","volume":"21","author":"Caso","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23507","article-title":"Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis","volume":"58","author":"Viguier","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/630620","article-title":"Angiogenic and inflammatory properties of psoriatic arthritis","volume":"2013","author":"Yamamoto","year":"2013","journal-title":"ISRN Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.39800","article-title":"Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis","volume":"68","author":"Abji","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18940","article-title":"Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker","volume":"183","author":"Abji","year":"2020","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1995-7645(14)60098-5","article-title":"Effect of pharmacological intervention on MIP-1\u03b1, MIP-1\u03b2 and MCP-1 expression in patients with psoriasis vulgaris","volume":"7","author":"Dai","year":"2014","journal-title":"Asian Pac J Trop Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113330","article-title":"Chemokine profile in psoriasis patients in correlation with disease severity and pruritus","volume":"23","author":"Purzycka-Bohdan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i2.32","article-title":"Sensitivity, specificity of biochemical markers for early prediction of endothelial dysfunction in atherosclerotic obese subjects","volume":"22","author":"Abulnaja","year":"2022","journal-title":"Afr Health Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02094-4","article-title":"Expression of ICAM-1 and E-selectin in different metabolic obesity phenotypes: discrepancy for endothelial dysfunction","author":"Liu","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00370-4","article-title":"Racial differences in prevalence and treatment for psoriatic arthritis and ankylosing spondylitis by insurance coverage in the USA","volume":"8","author":"Ogdie","year":"2021","journal-title":"Rheumatol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05322-5","article-title":"Racial disparities in comorbidities of patients with psoriatic arthritis","volume":"43","author":"Ross","year":"2023","journal-title":"Rheumatol Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"ard","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1229516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T14:50:13Z","timestamp":1689259813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1229516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2023.1229516"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1229516","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"article-number":"1229516"}}